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Abstract
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Spontaneous coronary artery dissection (SCAD) has emerged as an important cause of acute
coronary syndrome, myocardial infarction, and sudden death, particularly among young women
and individuals with few conventional atherosclerotic risk factors. Patient-initiated research has
spurred increased awareness of SCAD, and improved diagnostic capabilities and findings from
large case series have led to changes in approaches to initial and long-term management and
increasing evidence that SCAD not only is more common than previously believed but also must
be evaluated and treated differently from atherosclerotic myocardial infarction. High rates of
recurrent SCAD; its association with female sex, pregnancy, and physical and emotional stress
triggers; and concurrent systemic arteriopathies, particularly fibromuscular dysplasia, highlight the
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differences in clinical characteristics of SCAD compared with atherosclerotic disease. Recent
insights into the causes of, clinical course of, treatment options for, outcomes of, and associated
conditions of SCAD and the many persistent knowledge gaps are presented.

Keywords
AHA Scientific Statements; coronary artery dissection; spontaneous; fibromuscular dysplasia;
myocardial infarction; women
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Spontaneous coronary artery dissection (SCAD) is defined as an epicardial coronary artery
dissection that is not associated with atherosclerosis or trauma and not iatrogenic. The
predominant mechanism of myocardial injury occurring as a result of SCAD is coronary
artery obstruction caused by formation of an intramural hematoma (IMH) or intimal
disruption rather than atherosclerotic plaque rupture or intraluminal thrombus. Since the first
description of SCAD by Pretty1 in 1931 at autopsy, our understanding of it has evolved
tremendously during the past 8 decades, especially in the past 5 years. On the basis of
isolated case reports and small series, SCAD was initially described as a rare and almost
universally fatal cause of acute coronary syndrome (ACS), myocardial infarction (MI), and
sudden cardiac death in peripartum women,2–4 but contemporary reports have refuted these
misconceptions. Indeed, advances in our understanding of the epidemiology of SCAD, the
availability of intravascular imaging techniques,5 the development of SCAD-specific
angiographic classification,6 heightened awareness among providers, and parallel efforts by
patients7 using social media to broadly disseminate information suggest that SCAD is far
more common than previously thought, especially in young women. In addition, SCAD has
unique risk factors and associated conditions and different diagnostic, therapeutic, and
prognostic implications compared with atherosclerotic coronary disease.8–17
Despite these advances, dissemination of new knowledge has been slow, and SCAD
continues to be misdiagnosed, underdiagnosed, and managed as atherosclerotic ACS, which
may harm patients with SCAD. An emphasis on accurate diagnosis is key to not only
providing early supportive care but also ensuring that an invasive strategy of percutaneous
coronary intervention (PCI) be reserved for a select group of these patients because PCI for
SCAD has been associated with lower technical success and higher complications than PCI
for atherosclerotic disease.13,18–20 Increasing awareness of SCAD may overcome the limits
of existing literature, which often excludes sex-specific information, a gap that may have
clouded the understanding of this underrecognized condition.16,18,20–28
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The authors of this statement hope to spur a change in the paradigm of care for women and
men with SCAD. This American Heart Association scientific statement provides an
overview of current evidence and expert consensus with the aims of improving the
understanding and management of SCAD in the medical community and of enhancing
future collaborations and efforts to elucidate this still relatively poorly understood disease.
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EPIDEMIOLOGY

Author Manuscript

The true prevalence of SCAD remains uncertain, primarily because it is an underdiagnosed
condition. Missed diagnoses are driven by a low suspicion of ACS in young women even in
the presence of classic presenting symptoms, limitations of current coronary angiographic
techniques, and lack of clinician familiarity with the condition. SCAD most commonly
occurs in patients with few or no traditional cardiovascular risk factors.8–10,13,16,29 Recent
series using careful diagnostic criteria that exclude iatrogenic, traumatic, and atherosclerotic
dissection6 suggest that SCAD may be a cause of up to 1% to 4% of ACS cases
overall8,30–32 (Table 1), occurs overwhelmingly in women,8,11,13,30,31,33 may be the cause of
ACS in up to 35% of MIs in women ≤50 years of age,11,16,32 and is the most common cause
of pregnancy-associated MI (43%)17 (Table 2). Pregnancy-associated SCAD appears to
make up a smaller proportion of overall SCAD than early case series suggest,13,19,29,33,35
likely as a result of better detection of less severe SCAD among women who were not
recently pregnant.
The average age of women with SCAD ranges from 45 to 53 years, but examples of patients
presenting with SCAD in their second17 through eighth decades of life have been reported.
6,8,11,13,30,31,33,36 One study reported that men presented with SCAD at a slightly younger
age than women (mean age, 48.6 [SD, 9.8] years versus 52.3 [SD, 9.2] years; P=0.05).37,38
Although SCAD has been reported in all major racial and ethnic groups, the majority of
patients are white, a finding that may reflect referral and sampling bias and the demography
of patients cared for at reporting centers.8,13,15

Author Manuscript

The coronary distribution of SCAD has been well described. Although any artery can be
affected, the left anterior descending artery is the most commonly affected (32%–46% of
cases).8,10,13,16,19,33 In terms of territories, the left anterior descending and diagonal and
septal branches are affected in 45% to 61% of cases; the circumflex and ramus and obtuse
marginal branches in 15% to 45%; the right coronary artery and acute marginal, posterior
descending, and posterolateral branches in 10% to 39%; and the left main artery in up to 4%
of cases.10,11,13,16,19,33 In the majority of cases, the mid to distal segments of coronary
arteries are affected; in only <10% of cases are the proximal left anterior descending or
circumflex, right coronary, or left main arteries affected.13 Multivessel SCAD occurs in 9%
to 23% of cases.8,10,11,13,16,19,33,35

HISTOPATHOLOGICAL CLASSIFICATION AND FINDINGS

Author Manuscript

SCAD is characterized by the spontaneous formation of IMH within the wall of a coronary
artery (Figure 1). This has been confirmed by both intracoronary imaging39–42 and
histopathological case reports and series.43–55 More recent publications confirm historical
reports3,56,57 that describe the separation occurring in the outer third of the tunica media and
IMH occupying the dissection and compressing the true lumen, leading to coronary
insufficiency and MI47,50 (Figure 2).
Two theories of how SCAD develops have been described.58 The first theory proposes that
the primary pathological event is the development of a disruption in the vessel wall (intimal
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tear), which allows blood from the true lumen to enter and generate a false lumen. The
second theory proposes that the primary event is a spontaneous hemorrhage arising from the
vasa vasorum within the vessel wall.59 One group reporting an optical coherence
tomography series from patients with SCAD noted that an intimal rupture site could not
always be identified by this type of imaging, a finding supporting the second
pathophysiological theory in at least a proportion of cases.42,60 For cases in which an intimal
tear is identified, it remains unclear whether it is the initiating event or whether it is
attributable to increasing pressure in the false lumen causing reverse intimal rupture into the
true lumen or to the effect of coronary instrumentation during imaging.

Author Manuscript

There are several histopathological reports of a peri-adventitial mixed inflammatory
infiltrate, often with a predominance of eosinophils.44–46,49,50,52,54,55,61 However, there is
controversy about the pathophysiological significance of this eosinophilic infiltrate. Some
authors consider it pathognomonic for SCAD,3,54,62 and others attribute it to a nonspecific
response to vascular injury.50 The presence of an inflammatory cellular infiltrate
surrounding the dissection may be useful in distinguishing SCAD from iatrogenic
postmortem dissection, which can confound the diagnosis of true SCAD.50 Cystic medial
necrosis was reported in a few older series,63–65 but it has either been reported to be
absent44,49,53 or not commented on in reports since 2005. Fibromuscular dysplasia (FMD)
involving coronary arteries in which SCAD occurred has been described in several
histopathological case reports,53,66–68 an implication that coronary FMD was the cause of
SCAD and in keeping with the recently observed strong association between SCAD and
FMD.29,69
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In addition, the postmortem diagnosis of SCAD may be challenging, and a strong suspicion
coupled with careful coronary histopathological examination is required in cases of
unexplained sudden cardiac death.47,50 When SCAD is suspected to be the cause, especially
in young women, histopathological assessment of the coronary arteries should include distal
segments of the epicardial arteries because of the predilection of SCAD for middistal
coronary arteries.15

PATHOGENESIS OF SCAD AND SCAD-ASSOCIATED CONDITIONS
Because of the unique demographic and risk factor profile and the low prevalence of
traditional cardiovascular risk factors of SCAD,6,8–10,13,16,29 its cause is hypothesized to be
multifactorial with contributions from underlying arteriopathies, genetic factors, hormonal
influences, inherited or acquired arteriopathies, or systemic inflammatory diseases, often
compounded by environmental precipitants or stressors (Table 2).

Author Manuscript

FMD and Other Systemic Arteriopathies
Of the described arteriopathies, the association of SCAD with multifocal FMD in
extracoronary arteries has been the most commonly reported. FMD is a non-atherosclerotic,
noninflammatory vascular disease that can affect nearly any arterial bed and can manifest as
arterial stenosis, aneurysm, tortuosity, or dissection.70–72 Multifocal FMD is the most
common type of FMD and is defined angiographically as areas of alternating stenosis and
dilatation resulting in a string-of-beads pattern (Figure 3). Focal FMD appears
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angiographically as a single concentric or tubular narrowing; <10% of cases of FMD are of
this type. FMD is not currently considered a connective tissue disorder, which for the
purposes of this document refers to conditions in which arterial fragility is genetically
mediated.

Author Manuscript

First described in 2005 and subsequently confirmed in several case series, the association of
SCAD and FMD continues to be an area of considerable interest.69,73 Subsequent cohort
studies have shown a varying prevalence of concomitant FMD in extracoronary vascular
beds, ranging from 17% to 86%, depending on the patient population, number of imaged
vascular beds, and type of imaging used for screening.6,8,13,29,33,34,74,75 There is also
evidence that the prevalence of SCAD is not insignificant in patients with FMD. In the most
recent report on dissection and aneurysm in patients with FMD in the US Registry for FMD,
of the 237 of 921 patients (25.7%) who experienced ≥1 arterial dissections, 25 patients had
SCAD, representing 10.5% of all dissections and an overall prevalence of coronary
dissection of 2.7%.76 Case reports of typical histological and angiographic features of FMD
in coronary arteries, including from patients with a prior SCAD event,53,58,66–68,77–81 have
led some investigators to hypothesize that SCAD may be a manifestation of coronary FMD
in at least a proportion of SCAD events.82 Although FMD is the most common
extracoronary vascular abnormality identified among patients with SCAD, patients without
imaging signs of FMD have been reported to have other arterial abnormalities, including
dissections, aneurysms (including intracranial aneurysms in 14%–23%), or extracoronary
and coronary arterial tortuosity (78%).6,8,13,29,33,74–76,83 Some of these patients may indeed
have had FMD but it was not identified because of incomplete or insufficiently sensitive
imaging.
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Pregnancy and Female Sex Hormones
The term peripartum SCAD does not have a universal definition, and consistent with recent
designations, we have elected to use the term pregnancy-associated SCAD.84 Although
pregnancy-associated SCAD encompasses a relatively small proportion of SCAD cases,
13,19,30,33,84–86 it is the most common cause of MI among patients who are pregnant or
postpartum.17 A recent analysis of a US administrative database found a prevalence of 1.81
SCAD events per 100 000 pregnancies during pregnancy or in the 6-week postpartum
period.87 The majority of pregnancy-associated SCAD events occur in the third trimester or
early postpartum period, although SCAD has been reported as early as 5 weeks of gestation
and up to several months to a year or more postpartum, particularly in women who are still
lactating.35,85,86,88–90 The left main or left anterior descending artery has been described as
the most commonly affected.17,35,85,86,89,91,92
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The cause of pregnancy-associated SCAD is not fully understood. However, the hormonal
changes of pregnancy may lead to alterations in the architecture of the arterial wall.
17,84,91,93,94 One hypothesis suggests that the estrogen and progesterone receptors present in
the coronary arteries may mediate changes, as they do in other connective tissues, that
weaken the vessel wall, which culminates in arterial wall rupture, IMH, and onset of clinical
symptoms.17 Accumulation of these changes over several pregnancies may explain the
reported heightened risk of SCAD in multiparous women in some12,35,86,88 but not all87
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series. Demographic and comorbid conditions reported with pregnancy-associated SCAD
include black race, chronic hypertension, lipid abnormalities, chronic depression, migraines,
86,87 advanced maternal age and age at first childbirth, and treatment for infertility.
Gestational hypertension and preeclampsia have variably been associated.86,87 The average
age at the time of pregnancy-associated SCAD has ranged from 33 to 36 years, a finding
highlighting the potential impact of older age at time of pregnancy on cardiovascular
complications such as SCAD.85,86,88,89,95 Because maternal age and multiparity are
associated, the independent contribution of these factors to SCAD risk is uncertain.

Author Manuscript
Author Manuscript

Women with pregnancy-associated SCAD seem to have a poorer prognosis than women with
SCAD unrelated to pregnancy.85,86,88,89 In a series of 23 women with SCAD, 7 of whom
had pregnancy-associated SCAD, postpartum patients had larger infarcts, more proximal
artery dissections (86% versus 19%; P<.004), and lower mean left ventricular (LV) ejection
fraction (34% versus 49%; P<0.01).85 In the Mayo Clinic SCAD Registry, 54 women with
pregnancy-associated SCAD were compared with 269 women with non–pregnancyassociated SCAD. Patients with pregnancy-associated SCAD were younger, were more
likely to present with ST-segment–elevation MI (50% versus 36%; P=0.013) and left main
and multivessel dissections, had poorer LV function immediately and at follow-up, and were
less likely to have concurrent FMD.86 In a recent literature review of 120 pregnancyassociated SCAD cases by Havakuk et al,96 73% of women were postpartum and 76%
presented with ST-segment–elevation MI. Maternal complications were common:
cardiogenic shock in 24%, ventricular fibrillation requiring defibrillation in 16%,
mechanical support in 28%, and an in-hospital mortality rate of 4%. It is unclear why
pregnancy-associated SCAD is associated with more aggressive and extensive dissections
than non–pregnancy-associated SCAD and why the majority of pregnant women are spared
from pregnancy-associated SCAD.84
Inflammatory Conditions

Author Manuscript

SCAD is not commonly associated with systemic inflammatory disorders. Laboratory
evaluation for inflammatory or autoimmune conditions is generally low yield but may be
considered in the post-MI setting, particularly in patients who have symptoms of or physical
examination findings of autoimmune or rheumatologic disease. SCAD has been described in
case reports of patients with various systemic inflammatory diseases, including systemic
lupus erythematosus,97–102 inflammatory bowel disease,103 polyarteritis nodosa,104
sarcoidosis,52 celiac disease,105 and cryoglobulinemia in the setting of hepatitis C.106 In
these series, underlying coronary vasculitis100 or systemic inflammation100 may have
contributed to the risk of SCAD, and larger cohort studies have shown that at least a small
proportion of patients have either underlying inflammatory diseases or short-term increases
in inflammatory markers.13,60 Taken together, these series indicate that underlying
inflammatory conditions may be predisposing factors in the development of SCAD in a
small proportion of patients. However, this possibility is based primarily on case reports or
series of a small number of patients with inflammatory diseases that do not control for the
prevalence of these conditions in the population reported and may represent coincidental
association, especially because there is no published pathological proof of causation.

Circulation. Author manuscript; available in PMC 2018 May 17.

Hayes et al.

Page 7

Inheritance and Genetics

Author Manuscript

Inherited arteriopathies and connective tissue disorders are infrequently reported as the
underlying cause for SCAD (≈≤5%).8,13,107 Vascular Ehlers-Danlos syndrome (caused by
mutations in COL3A1107–109), Marfan syndrome (caused by mutation in FBN1107–110),
Loeys-Dietz syndrome (caused by mutation in genes encoding members of transforming
growth factor-β signaling cascade such as TGFBRI, TGFBR2,111 and SMAD3112), and
other mutations have been implicated and are known to be associated with arterial fragility
and dissection, resulting in SCAD. Spontaneous arterial dissection without preceding
aneurysm formation, as occurs in SCAD, is characteristic of vascular Ehlers-Danlos
syndrome. SCAD has also been described in polycystic kidney disease.113–115

Author Manuscript

Outside the context of these known genetic conditions, however, SCAD does not seem to be
strongly familial. In the largest series to investigate family history (421 subjects), Goel et
al116 documented a family history of SCAD in a very low proportion of patients (1.2%). In
that study, both dominant and recessive modes of inheritance were suggested, but most
SCAD cases seem to be sporadic, and no genetic risk loci have yet been definitively
associated with SCAD. This lack of a consistent inherited genetic pathway appears similar
to FMD, for which, although heritability has been documented,70,117–120 genetic testing has
been largely unfruitful because of the absence of an identified monogenetic cause.121,122
Barriers to gene discovery in SCAD are related mostly to the rarity of the condition and its
predominantly sporadic nature. Sample collection is underway at multiple centers, and
collaborative efforts will likely be needed to obtain sufficient statistical power to discover
gene and gene-by-environment associations with SCAD.

Author Manuscript

Precipitants and Triggers
There appears to be a complex interplay between a vulnerable patient (ie, one with
underlying arteriopathy) and potential triggers6,8,13,29,38,123–128 (Table 2) that initiate a
spontaneous arterial tear or IMH. However, this connection is not the case for all patients,
highlighting the incomplete understanding of the pathophysiology of this disease process.
Furthermore, although the frequency of patient-reported precipitants of SCAD is relatively
high compared with that reported in a large multinational cohort of patients with ACS, there
may be recall bias in the reporting of events around a life-threatening event such as SCAD in
typically young and previously healthy individuals. Thus, the potential for overreporting is
important to consider.129

Author Manuscript

The most commonly reported precipitants are extreme physical or emotional stress. Among
168 patients at a single center, an extreme emotional (40%) or physical (24%) stressor was
reported before their SCAD event.13 Emotional stressors have more often been reported as
precipitants of SCAD in women than in men,38 whereas physical stressors such as intense
isometric exercise and weight lifting have more often been reported among men with SCAD.
8,38 Stress cat-echolamine surge during these events has been postulated to lead to coronary
artery shear stress that, at least in part, contributes to the pathophysiology of SCAD.
Although this hypothesis has not been specifically tested in patients with SCAD, a similar
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mechanism was proposed in other stress-induced cardiovascular conditions such as stressinduced cardiomyopathy (takotsubo syndrome).129,130
Unlike hormonal triggers related to pregnancy, other potential hormone-mediated SCAD
triggers such as the perimenopausal state, use of oral contraceptives, postmenopausal
hormone therapy (HT), infertility treatments, and high-dose corticosteroid administration
have less supportive data, although associations have been reported.6,29,125–127,131 The
biggest challenge for confirming any of these correlations is that the baseline prevalence of
these conditions is either common in the general population or unknown.

CLINICAL PRESENTATION

Author Manuscript

Although there are wide ranges of clinical presentations and severities of SCAD, patients
who survive and present for initial evaluation almost universally experience ACS and
increased levels of cardiac enzymes. As many as 2% to 5% of patients present in cardiogenic
shock.10,11 Among available series of patients presenting for evaluation, 26% to 87% of
patients with SCAD present with ST-segment–elevation MI, and 13% to 69% present with
non–ST-segment–elevation MI.10,11,13,16,19,33 Presenting symptoms are consistent with
atherosclerotic ACS, with chest pain being the most prevalent132 (Figure 4). Ventricular
arrhythmias or sudden cardiac death account for SCAD presentation in 3% to 11% of
reported series.8,10,11,13,19 These reports must be interpreted with care because individuals
whose SCAD is not identified or is misdiagnosed, who do not survive to initial evaluation, or
in whom coronary imaging or postmortem evaluation is not performed are not included in
these studies.

Author Manuscript

Cardiac enzyme levels are almost invariably increased, although the initial troponin level in
patients with SCAD presenting to the emergency department may be normal.19,133 In a
cohort of 168 patients with SCAD from Vancouver, all patients had an increased troponin I
level; the median increase was 6 μg/L (normal, <0.05 μg/L), and the interquartile range was
broad (0.7–200 μg/L).13 In a Japanese cohort of 63 patients with SCAD, the mean peak
creatine kinase level (normal, 25–250 IU/L) was lower in young women with SCAD than in
patients without SCAD (1689 versus 2874 IU/L; P=0.025).11 LV wall motion abnormalities
detected on echocardiography or early angiography were common, but overall LV ejection
fraction was often preserved.19,134

DIAGNOSIS

Author Manuscript

Patients with SCAD are at risk of receiving alternative diagnoses and of being discharged
after emergency department evaluation because their relatively young age and absence of
atherosclerotic risk factors frequently do not fit the expected phenotype of an atherosclerotic
patient with MI. Accurate diagnosis of SCAD in the early stages of ACS presentation is
important because management and investigation are different from those for atherosclerotic
forms of coronary artery disease.12,19 The suspicion for SCAD is typically instigated by
clinical presenting features such as patient demographics, especially young age, female sex,
and few or no conventional cardiovascular risk factors. Once SCAD is suspected, coronary
angiography should be performed as early as feasible, especially in the setting of ST-
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segment–elevation MI. Despite the inherent limitations of conventional coronary
angiography that reduce the diagnostic capability for SCAD, this technique remains the firstline diagnostic imaging method because it is widely available and recommended for early
invasive management of ACS.135 The key limiting factor is that angiography is 2dimensional “lumenography” and does not specifically image the arterial wall.
Dedicated intracoronary imaging methods, including intravascular ultrasonography and
optical coherence tomography, provide detailed visualization of the arterial wall that aids the
diagnosis of SCAD. However, these tools have additional risks and costs, and they are not
readily available in all catheterization laboratories. Thus, availability, competence, and
expertise can vary widely with these technologies. As a consequence, conventional coronary
angiography remains instrumental in diagnosing SCAD, and cardiologists should become
pro-ficient at recognizing its various angiographic patterns.

Author Manuscript

Coronary Angiography
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The traditional angiographic description of SCAD emphasized the presence of multiple
radiolucent lumens and extraluminal contrast staining, which may have included spiral
dissection or intraluminal filling defects.136 However, contemporary angiographic SCAD
series have since shown that this “pathognomonic” appearance is present in only a small
proportion of SCAD cases.6,41 Addressing the drawbacks of prior descriptions, a specific
SCAD angiographic classification was proposed and now has been commonly adopted.6 In
the Saw angiographic SCAD classification, type 1 refers to the classic appearance of
multiple radiolucent lumens or arterial wall contrast staining (Figure 5A). Type 2 refers to
the presence of diffuse stenosis that can be of varying severity and length (usually >20 mm;
Figure 5B): Variant 2A is diffuse arterial narrowing bordered by normal segments proximal
and distal to the IMH, and variant 2B is diffuse narrowing that extends to the distal tip of the
artery.58 Type 3 is focal or tubular stenosis, usually <20 mm in length, that mimics
atherosclerosis (Figure 5C); intracoronary imaging is required to confirm the presence of
IMH and to diagnose SCAD (Figure 5D).
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Several studies have reported that the diffuse smooth stenosis pattern (ie, type 2) is the most
common angiographic manifestation of SCAD,11,13,16,41 occurring in up to 67.5% of
dissected arteries, followed by type 1 in 29.1% and type 3 in 3.4%.13 Thus, reliance solely
on the traditional multiple lumens or contrast staining of arterial walls to diagnose SCAD
would result in missed diagnoses of >70% of SCAD cases. Therefore, familiarity with the
diffuse narrowed-lumen appearance of IMH and use of intracoronary imaging are important
steps to improve the diagnosis of SCAD. Care must be taken to ensure that SCAD is not
misinterpreted as normal coronaries, atherosclerotic disease, coronary vasospasm,
thromboembolism, or takotsubo syndrome.137,138
Although coronary angiography is the standard for the diagnosis of SCAD, this invasive
procedure has intrinsic risk. Iatrogenic catheter-induced coronary artery dissection is
reported to be increased in patients with SCAD; the reported overall prevalence is 3.4%,
139,140 whereas it is <0.2% for standard coronary angiography.139,140 Underlying arterial
fragility in patients with SCAD is believed to accentuate the risks for iatrogenic dissection.
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Intracoronary imaging has become instrumental to aid the diagnosis of SCAD in
angiographically subtle or non-diagnostic cases. Fortunately, the need to use intracoronary
imaging has diminished in recent years because of improved SCAD-pattern recognition on
coronary angiography. Intravascular ultrasonography has been available for >20 years, and it
offers good spatial resolution of ≈150 μm to image the coronary arterial wall. It can detect
intimal tear, false lumen, IMH, and intraluminal thrombi, although its resolution may not be
adequate to clearly identify all such abnormalities related to SCAD.42,141 It has the
advantage of deep penetration to assess the depth and extent of IMH. Optical coherence
tomography is a more advanced technology that uses light waves to image the arterial wall.
This technology has revolutionized the diagnosis of SCAD since its first reported use in
2008.5,13,34,40,41,69 It has a spatial resolution of 10 to 20 μm, and thus, it is superior to
intravascular ultrasonography for delineating the lumen-intimal interface and is better for
visualizing intimal tears, false lumen, IMH, and intraluminal thrombi (Figure 6). This
superior imaging improves the ease of detecting SCAD and is the preferred intracoronary
imaging method when angiographic diagnosis is uncertain and when it is believed that
intravascular imaging can be safely undertaken.12 Nevertheless, both optical coherence
tomography and intravascular ultrasonography can provide complementary details for
diagnosis of SCAD, which on intracoronary imaging requires the presence of IMH or double
lumen.60 Because not all laboratories have both technologies accessible, angiographers
should become familiar with interpreting features of SCAD with their available
intracoronary imaging method.

Author Manuscript

Despite the importance of intracoronary imaging for the diagnosis of SCAD, these tools
have potential risks, including extending the coronary dissection with wire or imaging
catheter, guide-catheter iatrogenic dissection,139 catheter-induced occlusion of true lumen,
and hydraulic extension with contrast injection for optical coherence tomography. With
weighing of the risks and benefits, intracoronary imaging should be pursued only when
coronary angiographic diagnosis is uncertain (eg, type 3 or unclear lesions) and when the
vessel diameter is large enough for intracoronary imaging. In addition, there is generally no
clinical indication to evaluate the full depth and extent of IMH or false lumen because
conservative management is typically preferred. Therefore, intracoronary imaging can be
limited to the proximal segment of dissection without the need to image the entire dissected
segment. An algorithm for the angiographic diagnosis of SCAD is presented in Figure 7.
Coronary Computed Tomography Angiography

Author Manuscript

Cardiac computed tomography angiography (CCTA) of the coronary arteries is emerging as
an efficient tool for coronary assessment in low- and intermediate-risk patients presenting
with ACS.142–146 Although the role of CCTA in patients with uncertain ACS diagnoses is
promising, no dedicated study has addressed CCTA in the setting of acute SCAD. CCTA is
generally contraindicated in patients presenting with high-risk ACS and is not recommended
as the first-line investigation for suspected acute SCAD.143,147,148 Moreover, normal results
on CCTA do not exclude SCAD. Coronary dissection seen on retrospective evaluation of
initially negative CCTA images after SCAD was angiographically proved149 reinforces the
need for CCTA or “triple rule-out” protocols that include CCTA to be interpreted with great
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caution when SCAD is in the differential diagnosis as a means to minimize false-negative
results.147,148

Author Manuscript

Shortcomings of CCTA for SCAD include lower spatial and temporal resolution than
coronary angiography,150 inclusion of patients with a low pretest probability for
atherosclerotic coronary artery disease that thereby possibly affects the interpreters’
judgment, and a SCAD coronary appearance on CCTA that differs from that of typical
atherosclerosis.149,151 Coronary atherosclerosis on CCTA commonly appears as discrete
calcifications or focal dense, noncalcified plaques, whereas SCAD vessels may appear as
having dual lumens on CCTA with contrast agent in the dissected plane. Most commonly,
however, SCAD occurs without intimal disruption such that the contrast agent does not
opacify the false lumen.58 Although in such cases the coronary artery narrowing and IMH
are sometimes visualized on CCTA, these unique features can be challenging to recognize or
are unidentifiable in small vessels.58,149,151 Poorly gated or nongated computed tomography
angiography (such as computed tomography for pulmonary embolus) is inadequate for
coronary artery assessment.53,149,152,153
CCTA may be useful for noninvasive follow-up of patients with SCAD, particularly in those
with dissections in proximal or large-caliber coronary arteries.151,154,155 A study of 24
patients with SCAD who had follow-up CCTA found it to be a valuable, noninvasive study
without complications and identified healing in most (83%).155 SCAD involvement of distal
coronary arteries or side branches, or of vessel caliber <2.5 mm, generally is not well
visualized on CCTA; therefore, this method is of limited value in many SCAD cases.6,13

INITIAL MANAGEMENT
Author Manuscript

The American College of Cardiology/American Heart Association and the European Society
of Cardiology guidelines for the management of ACS advocate an early invasive strategy
with revascularization of culprit lesions over conservative therapy alone.156,157 This stentbased lesion pacification reduces the risk of recurrent occlusion at the lesion site and
associated adverse events in atherosclerotic MI, but there have been no randomized studies
or subgroup analyses of treatment outcomes or comparisons between acute revascularization
strategies for ACS caused by SCAD. These studies are critical because the mechanism of
vessel obstruction, the acute vessel response to balloon dilation, and the natural history of
conservatively managed lesions differ significantly in SCAD compared with atherosclerotic
ACS.
Conservative Management

Author Manuscript

No comprehensive prospective studies have routinely performed angiographic restudy after
SCAD, but observational data have indicated angiographic “healing” of SCAD lesions in the
majority of patients (70%–97%) who were selectively restudied weeks to months after a
conservatively managed index episode.6,8,16,19,33,41 A minority of patients had persistent
dissection on angiography,8,13,19 and it is unclear why dissection persisted in these cases or
whether very late healing may have occurred subsequently. The time course of healing
remains uncertain, but it can be detected within days8,13,158 and is frequently observed by 1
month.8,13 In an observational study of 131 SCAD lesions that had repeat coronary
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angiography, spontaneous healing occurred in 88.5% of cases. For the cases in which repeat
angiography was performed early (<35 days from index event), there were residual
dissections. However, repeat angiography performed after 35 days showed angiographic
healing in all cases.139 These results suggest a time dependency for healing to occur.

Author Manuscript

Of note, early complications of recurrent MI may develop in 5% to 10% of conservatively
managed patients, mostly related to extension of dissection within the first 7 days after an
acute episode.8,10,13 The majority of these patients require emergency revascularization, and
no angiographic or clinical predictors of acute worsening have been identified. Because of
these findings, inpatient monitoring for an extended period is typically recommended as part
of a conservative strategy for SCAD management.12,19,159 Conservative therapy may not be
appropriate in high-risk patients with ongoing ischemia, left main artery dissection, or
hemodynamic instability. In such cases, it is the consensus of the working group that urgent
intervention with PCI or coronary artery bypass grafting (CABG) should be considered, but
such decisions should be individualized and contemplated in the context of the coronary
anatomy and the expertise of the operators or centers. A proposed algorithm to guide
conservative versus invasive management is outlined in Figure 8.
Percutaneous Coronary Intervention

Author Manuscript

Observational studies have shown consistently that PCI for the treatment of SCAD is
associated with an increased risk of complications8–11,13,16,19,33 and suboptimal outcomes.
Affected coronary arteries may be inherently weak architecturally as a result of underlying
arteriopathies, which can render them more susceptible to iatrogenic dissections and
extension of dissections with PCI. Coronary guidewires may enter the false lumen and
occlude the true lumen. Balloon dilation and stent placement can also confer risks of
extending dissection of the intima or propagating IMH upstream and downstream from the
vessel, causing worsening of vessel obstruction. Such extensions of dissection can be
clinically significant, with some resulting in spiral dissections to the distal arterial segments
or retrograde dissection into proximal arteries and adjacent branches, including the left main
coronary artery. Given that dissection lengths are often extensive, complete PCI may require
long coronary stents, which can increase the risk of subsequent instent restenosis and stent
thrombosis. In addition, SCAD most frequently affects the distal coronary segments, which
may be too small or too distal for stent implantation. Moreover, IMH naturally resorbs over
time, which can result in subacute and late stent strut malapposition, potentially
predisposing to future risk of stent thrombosis.158,159
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These technical complications have been associated with adverse clinical outcomes in
several series. The Mayo Clinic series of 189 patients showed PCI technical failure in 53%
of the patients initially managed with PCI.19 Even when the percentage of residual stenosis
was ignored as a parameter, technical failure occurred in 30%. Emergency CABG was
required in 13% of those treated with primary PCI; emergency repeat PCI was required in
4%; and there was 1 death. Similar rates of adverse technical and clinical outcomes occurred
whether there was impaired flow or normal or near-normal vessel flow at baseline.19 In the
Vancouver cohort of 168 patients, technical failure occurred in 36%, stent thrombosis in 6%,
and emergency CABG as a complication of PCI in 12%.13 Similarly, in a European study of
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134 patients, 27% of PCIs resulted in technical failure, and 9% of patients required
emergency CABG.10
Optimizing PCI Approaches
Improving the outcomes of PCI in SCAD requires meticulous angiographic and
instrumentation techniques, including avoidance of deep catheter engagement, noncoaxial
positioning of catheter tip, catheter dampening, and strong contrast agent injection. In
addition, in potential SCAD cases, preferential use of femoral access or extra caution with
radial catheterization should be considered in light of a retrospective series in which there
was a 3-fold higher risk for catheter-induced iat-rogenic dissection in patients with SCAD
undergoing coronary angiography when radial access was used as opposed to femoral
access.13,139
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Multiple interventional strategies have been described when PCI is pursued for SCAD
lesions; however, no comparative studies have assessed the superiority of such techniques.
Examples of approaches that have had successful outcomes include the following: (1)
implantation of long drug-eluting stents covering in excess of 5 to 10 mm on both proximal
and distal edges of the IMH so as to accommodate propagation of the IMH when
compressed by the stent; (2) direct stenting without balloon predilation to avoid additional
risks of extension of the IMH; (3) balloon angioplasty alone to restore coronary flow without
stenting; (4) cutting balloon fenestration of the IMH to allow decompression of the false
lumen blood pool into the true lumen160,161 with or without additional stenting
(acknowledging the theoretical risk of coronary rupture, cutting balloon inflation should be
performed cautiously with an undersized balloon); (5) multistent approach by sealing distal
and proximal ends first with stents, before stenting the middle, to minimize IMH
propagation162; and (6) use of bioresorbable stents to provide a temporary scaffold because
complete resorption of struts occurs within 2 years.158,163 Finally, after successful PCI, dualantiplatelet therapy should be administered according to the stents implanted.158,164,165
Coronary Artery Bypass Grafting

Author Manuscript

Published evidence on CABG after SCAD is limited to case reports, small case series, and
retrospective observational studies with small sample size. CABG has been described as a
treatment strategy for SCAD in patients with left main stem or proximal dissections, after
technical failure of attempted PCI, when there is a complication of attempted PCI, and when
ischemia is refractory despite attempted conservative therapy. Use of arterial and venous
bypass conduits has been described, as have off-pump and robotic approaches.166–168 One
study reported high rates of initial technical success and inhospital clinical outcomes with
CABG as an index treatment strategy (n=20 patients, 32 conduits).19 Although these
findings provide some reassurance for CABG as a viable revascularization option for acute
SCAD, caution should be used in the overinterpretation of the data given the almost certain
selection bias for patients deemed to have suitable anatomy. During long-term follow-up, 1
study reported a high rate of both venous and arterial conduit failure (11 of 16 graft failures
from 11 of 20 patients undergoing follow-up angiography), almost certainly the result of
subsequent healing of native SCAD vessels and competitive flow promoting graft occlusion.
The study also showed that CABG was not protective against recurrent SCAD events.19 The
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use of vein grafts may be considered in light of frequent late graft failure and the opportunity
to preserve arterial conduits for the future.
In summary, on the basis of the retrospective observational data cited above, conservative
therapy is generally the preferred strategy in patients with SCAD who are clinically stable
and without objective evidence of ongoing ischemia and has generally been associated with
favorable outcomes.9,19 A conservative strategy is additionally appropriate in patients with
occluded distal vessels or distal branches that would not routinely be amenable to PCI.

EARLY SCAD OUTCOMES: IMPLICATIONS FOR DURATION OF
HOSPITALIZATION
Author Manuscript

Although rates of in-hospital mortality are low, up to 14% of patients require urgent inhospital revascularization, usually because of extension of dissection. Recognized
complications of SCAD depend on the initial treatment strategy (Table 3). Acknowledging
the biases associated with selected retrospective series, among reports including >100
patients,10,13,19 49.7% to 89.7% received medical therapy as initial treatment, and 2.6% to
8.5% of conservatively treated patients eventually required revascularization during the
index hospitalization. Revascularization with PCI was the initial treatment for SCAD in
16.7% to 47.1% of patients. Reported PCI success rates varied (36.4%–72.5%), most likely
because of the wide variability in the definition of PCI success in SCAD, but all were
substantially lower than success rates reported in control subjects with atherosclerotic ACS.
Emergency CABG was required in 2.2% to 7.4% of patients who initially received medical
therapy or PCI. An initial CABG revascularization approach was used in 0.6% to 3.7%, and
initial success (87.5%–100%) was high in this small group of patients.

Author Manuscript
Author Manuscript

In current clinical practice, the duration of hospitalization after ACS is therefore largely
dictated by the management strategy for the patient and the ongoing symptoms.172 All
patients with acute MI caused by SCAD are typically admitted for a minimum of 48 hours to
allow adjustment of medications and in-hospital evaluation of physical activity tolerance
before discharge.12 A prolonged period of in-hospital monitoring (3–5 days) is justified as
part of a conservative strategy to observe for a small but important (5%–10%) early hazard
of dissection extension or new recurrent SCAD.13,19 If clinical worsening occurs despite
conservative management (worsening of symptoms together with evidence of ischemia by
electrocardiography or significant arrhythmia), repeat angiography should be performed and
emergency revascularization undertaken to relieve ischemia if feasible. Chest pain does not
necessarily imply active myocardial ischemia. Chest pain may be a manifestation of vessel
wall dissection itself. Thus, chest pain alone should not be an indication to pursue
emergency revascularization, especially if there is no evidence of ischemia or if the vessel
flow is normal. Patients in whom PCI is unsuccessful or complicated by extension of
dissection, ongoing ischemia, ventricular arrhythmias, or heart failure often require longer
hospitalizations, similar to conservatively treated patients.
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Data on the use of therapies supportive of LV function or for persistent ischemia in SCAD
are limited to single-patient case reports, each with a favorable outcome. Intra-aortic balloon
pump counterpulsation has been used mostly to support surgical revascularization or
sometimes to bridge pregnant patients through surgical delivery before CABG.173–181 LV
assist devices or extracorporeal membrane oxygenation has been used as a bridge to
transplantation or to support recovery after CABG.175,177,180,182–186 In 1 case,
extracorporeal membrane oxygenation was used for cardiogenic shock after SCADassociated cardiac arrest treated with PCI and was a successful bridge to myocardial
recovery.180 The favorable outcomes in all reported cases likely represent a reporting bias
given the high-risk scenarios described. The theoretical risks of percutaneous support
devices in the setting of SCAD compared with atherosclerotic ACS include an increased
propensity for iliac or femoral arterial dissection with the placement of large-bore catheters
in the presence of FMD or other arteriopathies and hydraulic extension of intimal coronary
dissection with increased diastolic coronary flow during intra-aortic balloon pump
counterpulsation. Therapies supportive of LV function can be considered in cases of
cardiogenic shock after SCAD as a bridge to recovery or transplantation. No data are
available to support unique strategies in SCAD that differ from current consensus
recommendations in this area.187
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The role of implantable cardioverter-defibrillators or use of external defibrillator vests in
patients with SCAD who present with sudden cardiac arrest temporally related to their
ischemic event has not been studied. Patients with SCAD have been reported to receive early
implantation of cardioverter-defibrillators or more aggressive management despite the
absence of high-risk features such as recurrent arrhythmia, LV dysfunction, or persistent
ischemia.188 There are potential harms with this unproven aggressive practice, and currently,
there is insufficient evidence to suggest altering clinical decision making for implantation of
cardioverter-defibrillators on the basis of the cause of the ischemic event.172,189

MEDICAL THERAPY

Author Manuscript

The ultimate goals of short- and long-term medical therapy of SCAD are to alleviate
symptoms, to improve short- and long-term outcomes, and to prevent recurrent SCAD.
Unfortunately, there is a substantial gap in evidence to guide clinicians in this regard because
of the relatively recent recognition of SCAD as an important clinical entity and the absence
of identified cellular and molecular targets or randomized controlled trials to support an
evidence-based approach. Given the paucity of evidence currently available, the following
approaches are based largely on expert opinions derived from the clinical experience of
members of the writing group.
Anticoagulation and Antiplatelet Therapy
Because the pathophysiology, mechanisms of ischemia, PCI outcomes, and residua of
SCAD are distinct from those associated with atherosclerotic ACS, many investigators have
questioned the rationale and potential risks of using standard ACS therapies in patients with
SCAD. For instance, early heparin use may provide benefit by reducing thrombus burden,
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but there are theoretical concerns about its use in the setting of acute SCAD presentation
related to accentuating the risk of bleeding into the IMH or extension of dissection.
Therefore, if systemic anticoagulation is started at hospital presentation, in the absence of
other indications for systemic anticoagulation, consideration of discontinuation is
appropriate once SCAD is diagnosed.190
Similarly, there are no data to guide the use of glycoprotein IIb/IIIa inhibitors in the
emergency management of SCAD. Theoretical concerns about the extension of dissection,
additional bleeding risk, and absence of evidence of benefit suggest a cautious approach to
their use.190
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Patients with SCAD who are undergoing coronary revascularization should receive the
standard guideline-based antiplatelet therapy after PCI.156 Clear evidence supporting the use
of dual-antiplatelet therapy in patients with SCAD who do not undergo coronary
intervention is lacking. Although theoretical benefits of early dual-antiplatelet therapy in
SCAD include protection from additional thrombosis in the prothrombotic environment
caused by intimal dissection, many practitioners avoid its use in light of an increased
bleeding risk and no evidence of benefit. No study has compared short- or long-term
outcomes or bleeding risks related to the use of dual-antiplatelet therapy and aspirin alone in
SCAD.

Author Manuscript

In adherence with current guideline-directed use of antiplatelet therapy after ACS, some
experts recommend dual-antiplatelet therapy for at least 1 year after SCAD, regardless of
initial management strategy, along with lifelong aspirin use.156 Others opt for no or limited
use (1–3 months) followed by longer-term aspirin therapy. A retrospective Italian series
examining in-hospital and long-term clinical outcomes among patients with SCAD found
that dual-antiplatelet therapy with predominantly clopidogrel was administered to 82% of
conservatively managed patients and 94% of patients who underwent PCI.10 This therapy
was continued for a mean of 12.4 months (SD, 7.8 months) in patients who had stenting and
for 10.9 months (SD, 2.9 months) in those treated conservatively. Bleeding complications
were not reported, but long-term outcomes in both groups were similar.10
Most experts recommend aspirin use for at least 1 year and frequently indefinitely after
SCAD in patients who receive medical treatment, in the absence of contraindications.
10,31,190,191 In light of increased bleeding risks with antiplatelet agents, especially
menorrhagia in premenopausal women, and uncertain benefits and risks, individual selection
of suitability for dual-anti-platelet therapy and aspirin therapy in conservatively managed
survivors of SCAD is indicated.
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β-Adrenergic Blockers
β-Blockers should be considered in patients with SCAD who have LV dysfunction or
arrhythmias and for management of hypertension. Some experts advocate for their routine
use for SCAD12 on the basis of extrapolation from benefits in atherosclerotic MI135 or aortic
dissection,192 whereas others recommend that they be used selectively out of concern for
exacerbating vasospasm or symptomatic hypotension. In practice, β-blocker use is often
limited by adverse effects, especially symptoms of fatigue and hypotension. However, in a
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recently reported 327-patient series from Vancouver with a median duration of follow-up of
3.1 years, the use of β-blockers was associated with a hazard ratio of 0.36 for recurrent
SCAD in multivariable analysis,193 a finding strengthening the practice of β-blocker
administration after SCAD.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
After SCAD, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
should be used when MI is complicated by LV systolic dysfunction, according to national
guidelines for the management of patients after MI.135 These drugs are also a treatment
option for concomitant hypertension. Female patients of reproductive age must be warned of
the teratogenicity of renin-angiotensin system antagonists.
Statins
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In a retrospective cohort of 87 patients, no relationship was found between post-SCAD
medical management at discharge and SCAD recurrence, with the exception of statin use.
Statin use was higher in patients who had a SCAD recurrence; however, this finding may
have been affected by sample size, date of index event, and medication use that was started
after discharge.8 In a more recent 327-patient SCAD cohort, no association was found
between statin use and recurrent SCAD.193 Statin therapy is therefore not recommended
routinely after SCAD but is reserved for patients meeting guideline-based indications for
primary prevention of atherosclerosis194 and for the management of patients with
established concomitant atherosclerotic disease or diabetes mellitus.194
Antianginal Therapy
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The predominant role of antianginal therapies is for post-SCAD chest pain syndromes (see
Evaluation and Management of Chest Pain Syndromes After SCAD). Inpatient management
of chest pain may warrant antianginal therapy, but currently, there is not a role for the
routine use of antianginal therapy for either the index SCAD hospitalization or long term.
Chest discomfort is common in outpatients after SCAD, and for patients who are not
candidates for revascularization or who have evidence suggesting coronary vasospasm or
coronary microvascular dysfunction, relief of ischemia and symptoms may be achieved with
nitrates, calcium channel blockers, or ranolazine. Their use, however, must be balanced with
their adverse effect profile, most commonly symptomatic hypotension and headache
(nitrates).

PREGNANCY-ASSOCIATED SCAD: DIAGNOSIS AND SHORT-TERM
Author Manuscript

MANAGEMENT
The majority of pregnancy-associated SCADs occur in the first 4 weeks after delivery, but
SCAD has been reported during virtually all stages of pregnancy.86,96 Management of
SCAD in the pregnant or peripartum patient requires a multidisciplinary team
approach195,196 from cardiology and obstetric services that incorporates management for the
mother in combination with considerations for fetal well-being. Recommendations for
pregnancy follow-up and delivery after SCAD have been reviewed elsewhere and depend on
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both maternal and fetal status with the goals of limiting maternal hemodynamic demand and
close fetal monitoring.90 However, despite the special situation presented by pregnancy, the
principles of SCAD management are largely the same as for non–pregnancy-associated
SCAD, namely maintenance of a strong suspicion to ensure that the diagnosis is not missed,
early and careful angiography to avoid iatrogenic dissection196,197 and to confirm the
diagnosis (fetal radiation exposure is relatively low with current techniques90,198,199), and
aiming for conservative management if there is no evidence of ongoing ischemia or
infarction, hemodynamic instability, or particularly high-risk anatomy.17,200
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Special consideration must be given to post-SCAD pharmacotherapy recommendations for
women who are pregnant or lactating. Given the unclear usefulness of clopidogrel therapy in
SCAD, its use during pregnancy by women who do not undergo PCI should be
individualized.201 There are no clear safety data for clopidogrel use during pregnancy or
breastfeeding, and although there are case reports of it being used safely,202–204 it is
generally not recommended in women who are breastfeeding.205,206 Low-dose aspirin use is
safe during pregnancy and breastfeeding.195
Although β-blockers are associated with fetal growth restriction, they are routinely used
during pregnancy for the treatment of hypertension. Labetalol is the preferred agent,
especially in early pregnancy, because both metoprolol and atenolol are more highly
associated with lower placental and fetal weights at delivery.195,207 Atenolol has also been
associated with bradycardia in breastfed infants; therefore, it should also be avoided during
breastfeeding.206,208

CARDIAC REHABILITATION, PHYSICAL ACTIVITY, AND PSYCHOSOCIAL
Author Manuscript

CONSIDERATIONS AFTER SCAD
Cardiac Rehabilitation

Author Manuscript

All patients who have MI caused by SCAD should be referred for cardiac rehabilitation209
consistent with the secondary prevention, risk reduction, and psychosocial support strategy
recommendations.27,156,210,211 The program should be tailored and individualized, taking
into account not only cardiopulmonary factors such as ejection fraction but also patient age,
pre-SCAD physical activity level, and patient-centered recovery goals.211,212 Current
evidence in the SCAD population suggests low rates of both referral to and participation in
cardiac rehabilitation209,213,214 despite clear evidence of both safety and benefit, including
improved measures of physical and psychosocial well-being, improved metabolic
parameters, and lower symptom frequency.213–221 These low rates are compounded by the
lower overall referral of women to cardiac rehabilitation,216,222 healthcare providers’
reluctance to refer patients with SCAD for cardiac rehabilitation because of fears that
physical exertion will trigger recurrent SCAD, or the belief that relatively fit young patients
without atherosclerotic heart disease may not benefit from cardiac rehabilitation.215 Patients
with SCAD who enroll in cardiac rehabilitation often do not complete the program213,214
and may face barriers to participation unique to young women such as caregiving and work
responsibilities, travel concerns, cost, and ongoing symptoms.214,222
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In light of the association with physical activity as a trigger for SCAD, concern exists about
the safety of various forms of physical activity and exercise after SCAD.13,223 As a result,
and with the potential for physical and mental harm, some patients with SCAD continue to
receive advice to severely restrict their activities such as to avoid lifting >10 lb or not to
pursue activity beyond limited walking,220 which could place them at the risks associated
with a sedentary lifestyle. Many patients had high levels of physical activity before their first
SCAD event and express high levels of motivation to resume those activities.214 Therefore,
providers are encouraged to prescribe a prudent approach to physical activity, balancing
known benefits of exercise with the potential risks associated with high levels of exertion
and strain. Referral to and participation in cardiac rehabilitation are paramount for
addressing exercise-induced symptoms, providing immediate feedback on exercise
hemodynamics, and individualizing fitness needs.
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Although patients and providers want specific guidelines for or limits to physical activity, in
the absence of evidence for benefit or harm, arbitrary heart rate and weight lifting limits can
sometimes lead to frustration or fear with unclear benefit both during and after cardiac
rehabilitation participation. Clinicians may want to consider conservative thresholds for a
cardiac rehabilitation entrance exercise treadmill test that mirror those of the Vancouver
General Hospital SCAD Program (blood pressure no higher than 130/80 mm Hg; heart rate
50% to 70% of heart rate reserve; free weights for resistance training of 2 to 12 lb, starting
low and gradually increasing).214
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Weight training with resistance up to 20 lb for women and 50 lb for men was shown to be
safe in a small SCAD cardiac rehabilitation series.214,220 Strength training recommendations
are typically to use low resistance and high repetitions designed to avoid strain or Valsalva
maneuver. Cardiopulmonary stress testing after cardiac rehabilitation has been used by some
groups as a way of developing more precise and individualized parameters based on level of
fitness. This allows the development of parameters that avoid exercising near or above the
anaerobic threshold and for detection of exercise-induced hypertension.192,220,224
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In the absence of evidence for benefit or harm, such heart rate and weight lifting limits
remain arbitrary, and larger prospective studies are needed to confirm comparison with
standard cardiac rehabilitation programs or the safety of higher physical activity thresholds.
209,225 Current practice is based largely on clinical experience214,220 and recommendations
offered to patients with aortic dilatation or aortopathy,192,226 recognizing the substantial
differences in exercise-induced hemodynamics within the aorta and coronary arteries. In
addition to any symptom-limited physical activity guidelines, patients with SCAD should
generally be advised to avoid prolonged high-intensity activities, highly competitive or
contact sports, activities performed to exhaustion (racing, boot camp), abrupt increases in
physical activity without a warm-up, exercise in extremes of temperature (hot yoga, cold
weather) or terrain, or performance of Valsalva maneuver during lifting or exercise.
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Addressing mental health is a critical component of improving the short- and long-term
health of patients with SCAD. The psychosocial effects of a diagnosis of heart disease are
substantial, but patients with SCAD are a particularly high-risk population given that they
are predominantly younger women who have received a diagnosis with substantial
uncertainty in terms of management and prognosis. Anxiety and depression are common
among survivors of SCAD, especially in those whose SCAD occurred during the peripartum
period.225 In a recent cross-sectional study of 158 patients with SCAD, ≈40% reported a
history of depression and anxiety at any point in their life, and about one third reported
receiving medication or behavioral therapy for their anxiety and depression after their initial
SCAD.225 Baseline characteristics of patients with SCAD who participated in cardiac
rehabilitation showed that approximately one fifth214 to one third29 of patients reported a
history of depression. Compared with patients with non-SCAD MI, patients with SCAD MI
have higher psychological distress, depression and worry, anxiety, and tension scores on
psychosocial questionnaires.221
Patients with SCAD are an already high-risk group for psychological morbidity. Among all
patients with prior MI, younger women are at high risk for post-MI chest pain syndromes
compared with men and older women. They experience short- and long-term
outcomes20,227,228; angina229–231; psychosocial risk factors, including depression, anxiety,
and posttraumatic stress disorder; increased prevalence of stress or depression at the time of
MI230,232; more caregiving responsibilities233; lower health-related quality of life229,230; and
reduced physical and mental functioning after discharge.20,227–231,234 Current guidelines
recommend formal screening for depression and anxiety after MI,235 but younger and
female patients often do not receive these services.222
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Patients with SCAD also face unique issues. They are more often treated by a healthcare
team that has little familiarity with their condition or who voice uncertainty about the
diagnosis or treatment. They may be repeatedly advised to “change their lifestyle” as if they
had atherosclerosis, despite the absence of modifiable cardiovascular disease risk factors.
The lack of effective secondary prevention options can be anxiety provoking. Postpartum
patients have the additional burden of caregiving, hormonal shifts, peripartum mood
disorders, and disruption of expectations of early bonding with their infant or breastfeeding.
Most survivors of SCAD are fearful of resuming physical activities in light of the possibility
of triggering another dissection. The relatively uncommon nature of SCAD often results in a
lack of peer support. In addition, the medical jargon inundating patients with newly
diagnosed SCAD can often be intimidating; therefore, patient-focused medical literature
such as a “patient page” describing SCAD in lay terms can be helpful.236
Online communities and virtual peer support are especially important because patients may
be geographically separated from each other. The first SCAD-related international support
community was hosted by WomenHeart: The National Coalition for Women With Heart
Disease.237 Additional SCAD-specific patient support, advocacy, and nonprofit groups have
formed around the world to raise awareness of SCAD, to connect patients, and to
disseminate clinical practice and research developments. These organizations include SCAD
Alliance,238 Beat SCAD,239 and SCAD Research, Inc.240 In addition, numerous patientCirculation. Author manuscript; available in PMC 2018 May 17.
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initiated online communities have emerged on social media platforms. These organizations
and peer support groups have allowed geographically diverse survivors of SCAD to connect
with, to provide support to, and to receive support from peers.

EVALUATION AND MANAGEMENT OF CHEST PAIN SYNDROMES AFTER
SCAD

Author Manuscript

The collective experience suggests that chest pain is extremely common after SCAD,
occurring in more than half of outpatients.86,214 It is unknown whether chest pain is more
common in patients after SCAD than in sex- and age-matched control subjects after
atherosclerotic MI. The symptoms can challenge both patient and clinician and often result
in frequent evaluations, diagnostic testing, and substantial psychological burden. Post-SCAD
symptoms range from acute chest pain that is reminiscent of the patient’s SCAD presenting
symptoms, typical or atypical angina, to clearly noncardiac, but concerning, symptoms.

Author Manuscript

The differential diagnosis for patients who have chest pain syndrome after SCAD is similar
to that in patients after ACS, with the additional consideration of extension or recurrent
coronary dissection (Figure 9). An initial careful history and physical examination are
critical. The clinician should be vigilant for signs and symptoms of instent restenosis or
recurrent SCAD. The presence of noncardiac pain should be a diagnosis of exclusion, but
differentiating chest wall and musculoskeletal discomfort on the basis of reproducibility on
physical examination can be reassuring. If patients have more classic exertional symptoms,
then diagnostic testing such as an exercise treadmill test, stress echocardiography, or
perfusion imaging can be performed.25 If the study results are abnormal, coronary
angiography, CCTA, and initial medical therapy are options, depending on the severity of
symptoms and degree of ischemia. Alternatively, if symptoms are stable or there is evidence
of a noncardiac cause of the discomfort, patients can receive close monitoring for cardiac
symptoms, reassessment, and guidance on activities during cardiac rehabilitation.138,213

Author Manuscript

Frequently after SCAD, patients experience nitrate-responsive chest pain, often at rest or
with mental stress, but have no inducible ischemia with even high levels of exercise.
Premenopausal women may report chest pain at variable but predictable times of their
menstrual cycle.241 One hypothesis is that this is a result of enhanced coronary vasomotion
and abnormal endothelial function or persistent microvascular dysfunction. Clinically, some
of these patients respond to empirical use of long-acting nitrates or calcium channel
blockers, either daily or during days of the month when they are predictably symptomatic.
Although the use of these agents may be limited by adverse effects of hypotension or
headaches, empirical therapy may be considered if the patient’s symptoms are relieved with
short-acting nitrates. The frequency and severity of chest pain have been observed to
decrease over time, a result that may reflect vessel healing or resolution of stress, anxiety,
and depression.

CORONARY ARTERY ASSESSMENT AFTER SCAD
After the acute presentation, diagnosis, and in-hospital management of SCAD, there may be
reasons to reimage the dissected coronary arteries. Given the potential risks of iatrogenic
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dissections in patients with SCAD, repeat coronary angiography should be performed only
when benefits may outweigh the potential risks, such as in patients with recurrent symptoms,
abnormal functional tests, unclear cause of coronary stenosis (to assess for angiographic
healing to help differentiate SCAD from other coronary disease), or high-risk anatomy (eg,
left main, proximal, or multivessel dissection, in which residual dissections may benefit
from revascularization for high ischemic burden). The role of CCTA for reassessment after
SCAD was discussed previously. A summary of coronary imaging in the evaluation of postSCAD chest pain in the nonacute setting is outlined in Figure 9.

PREGNANCY, CONTRACEPTION, AND HORMONE USE AFTER SCAD

Author Manuscript

Given the concerns for possible recurrent SCAD on re-exposure to the physical, hormonal,
and potentially emotionally stressful conditions present during pregnancy and the
postpartum period and the current lack of secondary prevention strategies, many clinicians
recommend against subsequent pregnancy in women after SCAD, although there are few
data to support this potentially life-changing recommendation. In the only published series
to date examining subsequent pregnancy after a previous SCAD event, 8 patients were
followed up for a median of 36 months (inter-quartile range, 24±70 months). One of the 8
patients experienced recurrent SCAD after delivery, presenting with ST-segment–elevation
MI and ultimately requiring CABG because of unsuccessful PCI.242 Given the potential risk
of recurrent SCAD in a subsequent pregnancy and the accumulating evidence that
pregnancy-associated SCAD can result in worse outcomes,85,90,96 clinicians should carefully
counsel any patient contemplating pregnancy of the potential risk. Included in the
consideration are risks associated with medication use, functional status, and concomitant
myocardial or valvular dysfunction.

Author Manuscript

Patients who elect to attempt pregnancy after SCAD should be referred to tertiary medical
centers for preconception assessment and counseling, and those who become pregnant
without such consultation should seek early postconception evaluation and close follow-up
by a multidisciplinary team that includes maternal-fetal medicine specialists, cardiologists
with experience managing SCAD, and obstetric anesthesiologists. Patients should be
counseled on the potential increased risk of dissection and complications during the
pregnancy. The management of these patients should include careful review of their medical
regimen and adjustment or removal of medications that are unsafe or not recommended in
pregnancy (angiotensin-converting enzyme inhibitors, atenolol, statins) and cardiac testing,
including baseline electrocardiography and echocardiography.

Author Manuscript

Careful planning of the labor and delivery process and close postpartum care are essential.
90,209 Mode of delivery should be individualized, taking into account LV function, vascular
comorbidities such as FMD and vascular Ehlers-Danlos syndrome, and obstetric variables,
with a goal of minimizing intrapartum cardiovascular stress. Considerations include early
epidural placement, left lateral decubitus positioning, and treatment of hypertension.
Although there is insufficient evidence to guide optimal mode of delivery in patients with
SCAD, most cardiologists and maternal-fetal medicine specialists advocate for vaginal
delivery, similar to recommendations for women with systemic vascular or connective tissue
disorders. Other factors are the increased risk of hemorrhage, infection, thrombosis, and
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hemodynamic fluctuations with cesarean delivery in patients with cardiovascular disease.
Minimizing maternal effort during vaginal delivery, with passive descent in the
second stage of labor and delayed Valsalva effort, is advised; operative vaginal delivery or
cesarean delivery is used secondarily.195,197 Because SCAD occurs primarily in women and
is associated with pregnancy, there is a presumed pathophysiological association with female
sex hormones, although the precise relationship remains unclear. Although there is no direct
evidence linking hormonal contraception with recurrent SCAD, exogenous exposure to
systemically absorbed hormones, including estrogen and progesterone for contraceptive and
post-menopausal therapy, is usually avoided if possible, and they are used only if the
nonhormonal options have been considered and the benefits of HT outweigh potential risks.8
Preferred methods of contraception include vasectomy for the male partners of patients with
SCAD, tubal ligation (preferably performed once dual-antiplatelet therapy has been
stopped), and intrauterine devices with local delivery of progestin (levonorgestrel 20 μg/d).
Traditional or copper-containing intrauterine devices may be associated with increased
cramping and menorrhagia, particularly in women receiving aspirin or dual-antiplatelet
therapy.
197,243,244
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Many female patients with SCAD are faced with decisions about management of menopause
and post-menopausal HT. Compared with oral and transdermal hormonal contraceptives,
postmenopausal HT formulations have substantially lower levels of estrogen and
progesterone and have a lower risk of thrombosis, but concerns include the uncertain effects
of HT on SCAD incidence and recurrence and the absence of safety data available to guide
the initiation or continuation of HT specific to SCAD. Therefore, it is necessary to
individualize recommendations through the use of relevant consensus statements, guidelines,
245 and indications for use and to take into account patient preferences, known and perceived
risks and benefits, and symptom severity while recognizing that the risks of HT differ
depending on type, dose, duration of use, route of administration, timing of initiation, and
whether a progesterone is used.

Author Manuscript

Patients who experience SCAD while receiving HT should have their indications for HT
reassessed, and unless there are compelling reasons to continue, HT should be discontinued.
Indications for initiation of exogenous HT include premature and early surgical menopause,
severe vasomotor symptoms that cannot be managed with lifestyle or nonhormonal
treatments, and local treatment of genitourinary syndrome of menopause.245 If severe
vasomotor symptoms or genitourinary syndrome of menopause develop at menopause or
return on stopping the use of HT, consideration of the use of HT can be made in
collaboration with cardiovascular and menopause specialists. The appropriate, often lowest,
effective dose of systemic HT consistent with treatment goals that provides benefits and
minimizes risks for the patient should be the therapeutic goal. Locally applied vaginal
estrogen is generally thought to be safe because there is minimal systemic absorption.
Patients with cardiovascular disease are typically advised to use a transdermal systemic
agent to minimize activation of thrombotic factors and effects on lipids.246 The indications,
benefits, and risks of continuing or discontinuing use of HT should be reviewed periodically.
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MANAGEMENT OF ABNORMAL UTERINE BLEEDING AFTER SCAD
Antiplatelet therapy is frequently prescribed after SCAD, and many proposed therapeutic
regimens call for the use of aspirin and short-term use of clopidogrel after PCI. In this
setting, many women of reproductive age receiving dual-antiplatelet therapy report abnormal
uterine bleeding. The most common type related to this therapy is heavy menstrual bleeding,
defined as cyclic bleeding that is heavy for prolonged periods.247 Chronic or heavy bleeding
can result in anemia and pose a substantial disruption to activities of daily living. An
important first step is to reassess the indication for ongoing antiplatelet therapy and to
discontinue its use if appropriate.

Author Manuscript

When chronic heavy menstrual bleeding develops in women receiving antiplatelet therapy
after SCAD, especially if it is severe, they often require intervention to manage bleeding.
Patients with hemodynamic instability or bleeding that saturates a large pad or tampon
hourly for at least 4 hours usually warrant urgent evaluation, and all reproductive-age
women with abnormal uterine bleeding should be tested for pregnancy. In women without
cardiovascular disease, medical management with HT is usually sufficient and the first-line
approach to control most heavy menstrual bleeding, but this approach is relatively
contraindicated in SCAD, and careful clinical judgment is required. Other nonhormonal,
noncontraceptive options for treating abnormal uterine bleeding such as nonsteroidal antiinflammatory drugs and tranexamic acid should generally be avoided in women with SCAD
given their association with MI and thrombosis.248–250

Author Manuscript

Among medical therapies for heavy menstrual bleeding, progestin-eluting intrauterine
devices such as the levonorgestrel 20 μg/d–releasing device may be useful for controlling
bleeding and protect against pregnancy.251,252 Systemic progesterone levels may increase
minimally with these intrauterine devices, but the main effect is at the en-dometrial level.
The levonorgestrel 20 μg/d–releasing device is the most effective approach (comparable to
the efficacy of endometrial ablation), resulting in 71% to 95% reduction in menstrual blood
loss, and is the only progestin intrauterine device that has been evaluated for treatment of
abnormal uterine bleeding. In 2013, a lower-dose progestin device (releasing levonorgestrel
14 μg/d) became available253 and, if shown effective for management of abnormal uterine
bleeding, may afford advantages for patients with SCAD in light of lower hormonal
absorption. Although there are theoretical safety concerns, cyclic oral progestin treatment
has been found to reduce bleeding by 87%252,254,255 and generally results in irregular
bleeding and often reduction of menses to only light bleeding. In hemodynamically unstable
women in whom bleeding is not controlled, high-dose oral or injectable progestin-only
medications may be considered for the short term.
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Because patients with SCAD are generally advised to avoid both pregnancy and exogenous
hormones and because the long-term efficacy of conservative surgical treatment for heavy
menstrual bleeding such as second-generation endometrial ablation techniques (thermal
balloon, microwave, radiofrequency) is greater than that of oral medical treatment,256 these
interventions may be considered in the management of heavy menstrual bleeding after
SCAD. Advantages of these ablative procedures include effectiveness in managing bleeding,
reduction of pregnancy risk, and the ability to perform the procedure on patients without
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discontinuation of antiplatelet or anticoagulation therapy. Other surgical options to control
abnormal uterine bleeding are used primarily for women with structural abnormalities such
as polyps and fibroids. Balloon tamponade (30-mL balloon catheter) has been described as
an additional mechanical option to control acute bleeding in women who do not respond to
HT.

SCREENING FOR SCAD-ASSOCIATED CONDITIONS

Author Manuscript

In the majority of patients, SCAD is not an isolated event but is reflective of an underlying
vascular, genetic, or as-yet undetected condition. To help determine appropriate follow-up
evaluations, practitioners caring for patients with SCAD should obtain a careful history,
including a detailed review of systems and personal and family history of SCAD-associated
symptoms and conditions. A list of screening questions to consider in the evaluation of the
patient with SCAD is given in Table 4.

DIAGNOSIS OF SCAD-ASSOCIATED EXTRACORONARY ARTERIOPATHIES

Author Manuscript

FMD and other extracoronary vascular abnormalities are strongly associated with
SCAD13,34,257 and have the potential to affect management and inform prognosis. The
rationale for extracoronary vascular screening is to diagnose underlying associated
conditions such as FMD, which may point to a potential cause of SCAD, and to identify
other vascular abnormalities such as aneurysms or dissections that may require additional
evaluation, management, or longitudinal follow-up.75 Accordingly, all patients who have
experienced SCAD should undergo a complete vascular physical examination with palpation
and auscultation of the abdominal aorta, cervical carotid arteries, and peripheral arteries of
the upper and lower extremities. A diminished pulse, side-to-side asymmetry, or bruit may
be indicative of stenotic or dissected arteries, and widened or bounding pulse may be
indicative of aneurysmal disease. In the US Registry for FMD, the presence of an epigastric
or flank bruit had low sensitivity for the detection of renal FMD (24.0%); however, the
specificity and positive predictive value were 93.3% and 92.6%, respectively.257 Thus, the
absence of a bruit does not sufficiently rule out arterial disease, but its presence should
heighten suspicion of an underlying arteriopathy.

Author Manuscript

Given the high coprevalence of FMD, aneurysm, and other extracoronary vascular
abnormalities among patients with SCAD,13,34,70,76,258,259 vascular imaging from the brain
to pelvis should be considered in all patients, similar to current practice for FMD.70,71
According to the US Registry for FMD,257 the most commonly involved vascular beds are
the renal arteries (79.7%), followed by the extracranial carotid arteries (74.3%).70,257 Recent
imaging series among patients with SCAD reported the presence of intracranial aneurysm in
14% to 23%.13,75 In addition, several conditions associated with an increased prevalence of
unruptured intracranial aneurysms overlap with those associated with SCAD, including
FMD, vascular Ehlers-Danlos syndrome, Loeys-Dietz syndrome, and polycystic kidney
disease.257,260–264 The ultimate goal of vascular screening is the detection of high-risk
aneurysms or extracoronary abnormalities requiring treatment in order to avoid aneurysm
rupture and other complications associated with substantial morbidity and mortality.265–268
Screening for FMD and other extracoronary vascular abnormalities must include patient
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counseling for the possible outcomes, including a false-negative result (false reassurance), a
false-positive result (and the risk of further testing), a true-positive result with advice for
conservative management (and the potential for anxiety at the knowledge of harboring an
aneurysm or dissection), and a true-positive result with advice for treatment. In the case of a
true-positive result, there is a risk of treatment-associated harm (iatrogenic dissection,
stroke, aneurysmal rupture, and adverse effects of contrast agent).
Long-term management of FMD and other extravascular abnormalities is beyond the scope
of this statement, and we suggest using the approaches outlined in condition-specific
American Heart Association guidelines and scientific statements.70,226,268
Angiography
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The standard imaging method for diagnosing FMD is catheter-based angiography given its
superior spatial resolution (<0.1 mm), and it is the definitive test to diagnose cases that are
equivocal on noninvasive imaging.70 In patients undergoing coronary angiography to
diagnose SCAD, additional nonselective or selective renal and iliac artery catheter-based
angiography can be done in the same setting to assess for FMD. Similarly, for brain
imaging, 2-dimensional digital subtraction angiography has historically been the reference
standard for in vivo diagnosis of intracranial and cervical FMD and aneurysms, but the
superior detection of small aneurysms or subtle FMD compared with noninvasive testing
may not offer a clinically relevant advantage. Given this, as well as the low, but important,
rate of procedural complications, digital subtraction angiography is not generally used as an
initial method for cerebrovascular screening purposes but may be appropriate when the
diagnosis is still uncertain after noninvasive imaging or when intervention is contemplated.70
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Computed Tomography Angiography

Author Manuscript

In patients undergoing noninvasive imaging, the higher resolution of computed tomography
compared with that of magnetic resonance imaging and ultrasonography and the ease of
imaging across multiple vascular territories in a single scan may improve detection of the
vascular abnormalities that are often found in SCAD.76 Notably, the FMD findings in
patients with SCAD may be subtle and can be missed if not specifically sought. Regardless
of the imaging method chosen, careful and focused image interpretation is critical. Multiple
reconstruction formats, including multiplanar reformatted images, shaded surface display,
and maximum-intensity projections, are necessary to adequately review for changes of
FMD.70,269 For the detection of brain aneurysms, multirow detector computed tomography
angiography is generally the preferred noninvasive imaging method because it provides
detailed evaluation of the extracranial carotid, vertebral, and intracranial arteries for
potential aneurysms.70,270,271 The sensitivity for aneurysms <3 mm is 82%.271 Advances in
computed tomography technology such as third-generation dual-source systems continue to
drive down radiation exposure and further shorten scanning time while preserving or
improving image resolution. Novel protocols to image multiple vascular beds in a single
diagnostic session can facilitate patient convenience and diagnostic accuracy over magnetic
resonance angiography.75
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Magnetic resonance angiography has lower spatial resolution than computed tomography
angiography for FMD diagnosis,12,272 but newer magnetic resonance angiography can take
advantage of volume rendering and strong magnets (3.0 T) that have increased the sensitivity
for detection of aneurysms, despite the potential for false-negative and false-positive results.
273 Benefits of magnetic resonance angiography include the absence of radiation, highly
sensitive imaging of the brain parenchyma, and no requirement for contrast agent. The
technique is limited by contraindications to magnetic resonance imaging (implanted metal,
older pacemakers) and long scanning times that can lead to a higher likelihood of motion
artifact degrading the image.
Duplex Ultrasonography

Author Manuscript

Duplex ultrasonography for the diagnosis of FMD is challenged by the need for highly
skilled technicians and oversight by interpreting physicians.70 Given the lower sensitivity of
duplex ultrasonography compared with that of computed tomography angiography or
magnetic resonance angiography for FMD and other arteriopathies, this method has largely
been replaced by computed tomography angiography or magnetic resonance angiography in
most institutions for screening in the SCAD population.
Radiation Exposure: Special Considerations for Young and Female Patients
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The disadvantage of angiographic or computed tomographic approaches to screening for
extracoronary abnormalities and coronary imaging is the exposure to ionizing radiation.
Given that the majority of SCAD occurs in young patients and that imaging plays a critical
role in diagnosis and management, a discussion of radiation exposure is highly relevant. For
women, the lifetime attributable risk of cancer is estimated at 2- to 4-fold greater for an
exposure occurring at 20 versus 60 years of age compared with the risk in men.274 Because
these young patients have a longer potential lifespan and are at risk of recurrent SCAD
events and other conditions requiring imaging, there is an increased probability for multiple
imaging tests, repeated procedures, and multiple healthcare providers being involved in their
care. Cardiac imaging studies used in the evaluation of SCAD requiring ionizing radiation
(invasive angiography and CCTA, stress myocardial perfusion imaging with positron
emission tomography, and single-photon emission computed tomography) should be
performed only after individualized assessment of risks and benefits. Both technological and
operator radiation dose–reduction strategies should be used.275,276 Once systemic
arteriopathy is diagnosed or an extracoronary dissection or aneurysm is identified that
requires longitudinal follow-up, subsequent use of alternative imaging methods that do not
expose the patient to ionizing radiation (eg, magnetic resonance angiography, duplex
ultrasonography) should be considered.70,76 Particular efforts should be made to limit both
patient and offspring radiation and contrast agent exposure in pregnant or lactating patients
with SCAD, in whom non-emergency imaging should be deferred.199

ROLE OF GENETIC EVALUATION
The yield from routine genetic testing in patients with SCAD, especially among those
without a suggestive personal or family history or physical examination of an inherited
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systemic arteriopathy or connective tissue disorder, has been shown to be low,107 and in the
absence of a suggestive history or physical examination (Table 4), routine genetic testing
after SCAD is not currently advised. Similarly, in patients with FMD, screening for variants
in known arteriopathy-causing genes also seems to be of low yield.121,122 However, given
the known association of SCAD with several inherited arteriopathies, referral to a specialist
in medical genetics for further evaluation should be considered to aid in decision making for
formal genetic assessment if an underlying systemic arteriopathy or connective tissue
disorder is suspected in SCAD survivors. Patients with pregnancy-associated SCAD should
also be considered for this evaluation because an underlying arteriopathy may be triggered
by the hemodynamic and hormonal changes of pregnancy. Although the prevalence of these
disorders is low, the diagnosis of a systemic arteriopathy may influence recommendations
for frequency of vascular screening, timing of surgical intervention for aneurysms, or
assessment of risk of pregnancy in the case of vascular Ehler-Danlos syndrome. This
information can also guide screening in first-degree family members to determine their risk
of aneurysm or dissection and need for clinical screening.

Author Manuscript

Formal medical genetics consultation, and testing if indicated, should be performed at a
referral center with experience in genetically mediated arteriopathies and availability of
medical genetics specialists.277 Given the complex financial, insurance, familial, and social
issues surrounding genetic testing, genetic counseling is paramount before mutation
screening.277 During the clinical evaluation for a genetically mediated arteriopathy, family
history is assessed with a 3-generation pedigree, personal history, and examination for
features characteristic of connective tissue disorders, including features of Marfan syndrome
and other disorders caused by transforming growth factor-β pathway gene mutations, as
reviewed in the Inheritance and Genetics section. Mar-fan syndrome and neurofibromatosis
may be diagnosed clinically.278,279 Clinical findings of polycystic kidney disease should
prompt an evaluation, which may include gene testing in some cases.
When findings suggestive of an inherited disorder are present, sequencing of a panel of
genes inclusive of inherited arteriopathies (eg, TGFBR1, TGFBR2, COL3A1, FBN1,
ACTA2, SMAD3, PLOD1, and COL5A1) should be considered an efficient approach to
evaluate genetically mediated vascular disease. The history and physical examination may
be unrevealing in vascular Ehlers-Danlos syndrome, and thus, the threshold for COL3A1
mutation testing may be lower.
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Given the rapid expansion of identified genes for aortopathies, clinical genome sequencing
(focused on whole genome or exome) may provide a single source of genetic data in which
queries may be performed as new findings emerge. However, given the current lack of data
showing defined, specific genetic causes for SCAD and the sporadic nature of the disease,
routine whole-genome or exome sequencing is not currently recommended. In the absence
of a confirmed diagnosis of a heritable arteriopathy or connective tissue disorder, clinical
screening in first-degree family members of patients who experienced SCAD is not clearly
indicated.
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SCAD PROGNOSIS AND RECURRENCE RISK
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The short- and long-term prognosis and risks of SCAD recurrence are highly relevant and of
concern to both patients and their providers. After hospital dismissal, intermediate and longterm adverse cardiovascular events after SCAD are relatively common and include chest
pain, depression, anxiety, and major adverse cardiac events such as recurrent MI, recurrent
SCAD, unanticipated revascularization, congestive heart failure, stroke, and death. At an
intermediate-term follow-up of 2 to 3 years, major adverse cardiac events were reported in
10% to 30% of cases, mostly caused by recurrent MI from recurrent SCAD, reported in 15%
to 22% of patients.11,13,193 At longer-term follow-up, major adverse cardiac events were
reported in 15% to 37% at 5 to 7 years, and the Kaplan-Meier–estimated rate of major
adverse cardiac events is ≈50% at 10 years.8,10,13 These longer-term major adverse cardiac
events are related predominantly to recurrent SCAD, which was estimated at up to 30% at 4
to 10 years of follow-up in different series.8,11,13,19
The reported rates of a recurrent episode of SCAD vary considerably in the literature (0%–
37%),8–11,13,30,280 likely representing differences in study design, duration of follow-up, and
definition of recurrence. Historically, the term recurrent SCAD has been used relatively
interchangeably to describe 2 distinct forms of dissection: extension of the index dissection
in the acute phase resulting from expansion of the IMH of the unhealed SCAD lesion and de
novo dissection unrelated to the index dissection, affecting different coronary artery
segments and occurring later (>30 days) and remote from the index event.8,11,13,19,281 Given
the disparate features and pathophysiology of extension of dissection and de novo recurrent
dissection, the term recurrent SCAD should be limited to describe subsequent de novo
SCAD.
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When reports of recurrent SCAD are limited to subsequent de novo dissections, incident
recurrent SCAD rates are more consistent, and SCAD recurs in previously unaffected
arteries 77% to 100% of the time.8,11,13,19,281 In the Mayo Clinic series, SCAD recurred in
17% of patients (15 of 87) at a median time to the second episode of 2.8 years, and the 10year Kaplan-Meier–estimated risk of recurrence was 29.4%.8 In the updated series by Eleid
et al83 with 246 patients, the reported rate was 16% over a median duration of 1.7 years. In
the Japanese series, recurrent SCAD was reported in 19% of patients (14 of 63) at a median
duration of 42 days.11 In the 168-patient Vancouver series, recurrent SCAD was reported in
13% of patients (22 of 168).6 In the updated 310-patient Vancouver cohort, recurrent SCAD
occurred in 11% of patients (34 of 310); in all patients, new coronary artery segments were
affected, and the recurrence was 30 days (median, 3.6 years) after the index SCAD.281

Author Manuscript

Identification of risk markers or risk factors for recurrent SCAD has been and remains an
important clinical goal. Small sample size of studies has been a limitation, and to date, only
severe coronary tortuosity has been identified as a risk factor for recurrence, with recurrence
most likely to occur in a segment of tortuosity.83 Whether tortuosity itself confers a direct
pathophysiological risk or is simply a marker of a high-risk patient phenotype remains
uncertain. Coronary tortuosity was also shown to be a coronary manifestation of FMD12,82
and thus may be a confounder for the presence and strong association with FMD.
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Furthermore, the presence of FMD itself has not been identified as a predictor of recurrent
SCAD.83,193

RESEARCH PRIORITIES AND CALL TO ACTION

Author Manuscript

SCAD is an important cause of ACS in otherwise healthy young and middle-aged
individuals, particularly women without traditional cardiovascular risk factors. It is
frequently underdiagnosed or misdiagnosed and can potentially result in substantial
morbidity and mortality; a heightened suspicion for SCAD is required for accurate diagnosis
and treatment. Despite increased recognition of the condition by the medical community and
patients, large gaps in knowledge must be addressed to provide the best outcomes. It should
be acknowledged that only recently have there been even limited prospective studies, and
most available data are retrospective and observational. The findings are limited by referral
bias and survivor bias, both of which may serve to overestimate recurrence risk. Conversely,
the well-recognized sex bias in pursuing cardiac investigations in young women presenting
with chest pain, together with known challenges in diagnosing SCAD even when
investigations are undertaken, may serve to underestimate recurrence risk. Future largerscale prospective and epidemiological studies will help further our understanding of the
demographic, treatment, and anatomic factors associated with recurrence and allow more
accurate prediction and ultimate prevention of recurrent SCAD.
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The writing committee has classified research priorities into the areas of epidemiology,
pathogenesis, diagnosis, and treatment (Table 5), each with key questions intended to spur
collaborative research and advances in treatment for this disease. SCAD is an important
cause of MI, particularly in young women. Although several key questions have yet to be
answered, this writing group hopes that this document increases the awareness of SCAD
among physicians and other healthcare providers and thus improves the recognition and
management of SCAD. This awareness must then initiate collaborative research efforts to
help understand the natural history of SCAD and to develop therapies to prevent SCAD
complications and recurrence. We applaud the efforts of SCAD survivor–led initiatives,
which have sparked collaboration and research thus far. We also call on the medical
community to continue efforts to drive progress in this disease and to educate fellow
physicians about SCAD. We hope that this inaugural American Heart Association scientific
statement on SCAD becomes the catalyst for a call to action among the medical and patient
communities.
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Figure 1. Cross-sectional views of the coronary artery

A, Normal coronary artery. B, Coronary artery with intramural hematoma. C, Coronary
artery with intimal tear. Spontaneous coronary artery dissection is characterized by the
spontaneous formation of an intramural hematoma, which can lead to compression of the
true lumen and myocardial infarction. An intimal tear may be present. Created by and used
with permission from Dominic Doyle, MA.
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Figure 2. Pathological appearance of spontaneous coronary artery dissection

Author Manuscript

Histological (A) and pathological (B) appearances show compression or obliteration of the
true lumen (TL; arrows) by hematoma within the false lumen (FL). Used with permission
from Mary N. Sheppard, Department of Cardiovascular Pathology, St. George Medical
School, London, UK.
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Figure 3. String-of-beads appearance of multifocal fibromuscular dysplasia (FMD)

Author Manuscript

Selective angiography of the right renal artery (A) and computed tomography angiography
of the carotid (B) and renal (C) arteries. B and C are from the same patient. Findings of
FMD in the right renal artery are more subtle (C, arrow) but suggest FMD given obvious
beading elsewhere (B, red arrow). Also present in the bilateral internal carotid arteries is
aneurysmal dilatation (aneurysm vs pseudoaneurysm; B, white arrows).
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Figure 4. Frequency of presenting symptoms of acute spontaneous coronary artery dissection

VF indicates ventricular fibrillation; VT, ventricular tachycardia. Adapted from Luong et
al132 with permission. Copyright © 2017, Wiley Periodicals, Inc.
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Figure 5. Angiographic features of spontaneous coronary artery dissection

Author Manuscript

A, Type 1, multiple radiolucent lumens (arrow) or arterial wall contrast staining. B, Type 2,
diffuse stenosis that can be of varying severity and length (dissection starting from arrow).
C, Type 3: focal or tubular stenosis (arrow), usually <20 mm in length, that mimics
atherosclerosis. Intracoronary imaging should be performed to confirm the presence of
intramural hematoma or multiple lumens. D, Optical coherence tomography in type 3 (C)
shows intramural hematoma (asterisk).
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Figure 6. Intracoronary imaging for spontaneous coronary artery dissection

Author Manuscript

A, Optical coherence tomography shows intimal dissection (solid arrow) and intramural
hematoma (asterisk). B, Intravascular ultrasonography shows intramural hematoma (dotted
arrow) compressing the true lumen (asterisk).
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Figure 7. Algorithm for diagnosis of spontaneous coronary artery dissection (SCAD) in the
setting of acute coronary syndrome

CT indicates computed tomography; CTA, computed tomography angiography; FMD,
fibromuscular dysplasia; IC, intracoronary; IVUS, intravascular ultrasonography; MRA,
magnetic resonance angiography; and OCT, optical coherence tomography.
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Figure 8. Algorithm for management of acute spontaneous coronary artery dissection

CABG indicates coronary artery bypass grafting; PCI, percutaneous coronary intervention;
and Rx, management. aLeft main or proximal 2-vessel coronary artery dissection.
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Figure 9. Evaluation and management of chest pain after spontaneous coronary artery dissection
(SCAD).157,170
aCurrent

Author Manuscript

guidelines.135 bHigh-risk anatomy indicates SCAD affecting the left main or 2
proximal coronary arteries. cMedical management for post-SCAD chest pain (CP) without
obstructive disease: long-acting nitrates, calcium channel blockers, or ranolazine. ACS
indicates acute coronary syndrome; CA, coronary angiography; CAD, coronary artery
disease; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic
resonance; DDx, differential diagnosis; and echo, echocardiography.
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hCG indicates human chorionic gonadotropin; NR, not reported; and SCAD, spontaneous coronary artery dissection.
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n (%)

9 (66.7)

NR

NR

12 (91.7)

34 (91.2)

4 (100)

8 (75.0)

55 (72.5)

97 (47.4)

33 (36.4)

16 (81.3)

5 (60)

10 (NR)

13 (92.3)

11 (72.7)

1 (0)

All PCI
Attempts,
n. (%
success)*

1 (100)

23 (NR)

1

2 (100)

1 (NR)

0

0

8 (87.5)

20 (94.1)#

5 (100)

2 (50)¶

6 (NR)

NR

2 (NR)

5 (100)

6 (83.3)

All CABG
Procedures,
n (%
success)

0

NR

NR

NR

NR

0

0

7 (5.2)

NR

8 (4.8)

1 (2.22)¶

2 (8.7)

NR

NR

0

NR

InHospital
MI, n
(%)

0

NR

2 (15.4)

1 (2.5)

NR

0

0

7 (5.2)

26 (14)

8 (4.8)

7 (15.6)

4 (17.4)

NR

NR

3 CABG (13)

1 (16.7)

In-Hospital Urgent
Revascularizations,
n (%)

1 (1.6)§§

Left main SCAD complicated by cardiogenic shock not improved by salvage left main PCI.

Cardiogenic shock.

§

‡

Sepsis.

†

Success as defined per author or as patients not requiring second intervention for the same lesion.

*

3

1 (7.7)

0

NR

0

0

3 (2.2)††

1 (0.53)**

0

1 (2.22)¶

0

1 (8.3)§

0

1 (4.3)‡

1 (16.7)†

InHospital
Mortality,
n (%)

CABG indicates coronary artery bypass grafting; MI, myocardial infarction; NA, not applicable because all were treated with CABG; NR, not reported or able to be determined from data provided; PCI,
percutaneous coronary intervention; and SCAD, spontaneous coronary artery dissection.

Cade et

2017

2016

al89

McGrath-Cadell et

Nakashima et

Rashid et
2016

2016

al16

al171

2016

al155

al11

2015

Lettieri et al10

Roura et

2014

Tweet et al19

2012

2011

2014

al9

2010

2009

2009

2008

Year

Saw et al13

Alfonso et

Ito et al85

Motreff et

al170

Mortensen et al30

Vanzetto et al31

Unal et

al169

Reference

Crossover to
Revascularization,
n (%)

Author Manuscript
Initial
Medical
Therapy,
n (%)

Author Manuscript

Acute Revascularization Outcomes in SCAD

Author Manuscript
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Author Manuscript

Author Manuscript

Multiorgan failure after bailout CABG for unsuccessful PCI.

All cases pregnancy-associated SCAD.

Left main artery SCAD in late pregnancy, cardiac arrest during emergency cesarean delivery, refractory cardiogenic and hemorrhagic shock.

§§

‡‡

One patient died of retrograde aortic dissection after PCI; 1 patient died after emergency CABG for multivessel SCAD with ST-segment–elevation MI and cardiogenic shock; and 1 patient died of out-ofhospital cardiac arrest and cardiogenic shock with coronary anatomy not suitable for revascularization.

††

**

Two of 34 intended bypass targets unable to be revascularized because of extent of dissection.

#

Perioperative MI and death in a patient with severe 3-vessel coronary disease and concomitant atherosclerotic disease.

Eighteen patients in this cohort had concomitant atherosclerotic heart disease on angiography.

Author Manuscript

¶

Author Manuscript

||
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Table 4

Author Manuscript

Screening Questions for SCAD-Associated Arteriopathies and Connective Tissue Disorders
Personal history (Have you ever been diagnosed with or experienced any of the following?)
Early-onset hypertension
Stroke or transient ischemic attack
Pulsatile tinnitus
Migraine headaches
Renal infarction
Subarachnoid hemorrhage
Aneurysm (aortic, peripheral, brain)
Dissection (aortic, peripheral)
Rupture of hollow organs (intestinal, bladder, uterine)
Pneumothorax

Author Manuscript

Tendon or muscle rupture
Joint dislocation
Talipes equinovarus (clubfoot)
Umbilical or inguinal hernia
Scoliosis or pectus deformity
Pregnancy complications (cervical incompetence, hemorrhage, uterine prolapse, hypertension)
Poor wound healing
Ectopia lentis
Myopia
Detached retina, early glaucoma, or early cataracts
Tall stature
Abnormality of cardiac valve (bicuspid aortic valve, mitral valve prolapse)

Author Manuscript

Systemic inflammatory disease
Family history (Does anyone in your family have any of the following?)
Dissection (coronary, aortic, peripheral)
Inherited arteriopathy or connective tissue disorder (eg, vascular EhlersDanlos syndrome, Marfan syndrome, Loeys-Dietz syndrome)
Fibromuscular dysplasia
Aneurysm (aortic, peripheral, brain)
Early stroke, early myocardial infarction, sudden cardiac death
Review of systems (Are you currently experiencing any of the following?)
Headaches
Pulsatile tinnitus
Postprandial abdominal pain
Flank pain

Author Manuscript

Claudication
Easy bruising
Joint hypermobility or laxity

SCAD indicates spontaneous coronary artery dissection.
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Table 5

Author Manuscript

Research Priorities and Key Questions in SCAD
Epidemiology
What is the prevalence of SCAD in the general population?
Are there sex differences in the cause, presentation, diagnosis, and treatment of SCAD?
What is the recurrence rate of SCAD, and what are the determinants of recurrence?
Pathogenesis
Are there underlying genetic, hormonal, and environmental causes of SCAD, and what are the proportionate contributions of each?
What are the roles of physical and emotional stress and other potential triggers of SCAD?
What is the proportionate contribution of FMD and other systemic arteriopathies to the development and recurrence of SCAD?
Diagnosis
Under what circumstances and time frame and with what imaging method should follow-up coronary imaging be performed?

Author Manuscript

Treatment
What are the optimal approaches for initial revascularization?
What is the role of anticoagulation and antiplatelet therapy in SCAD immediately and after the event?
What are appropriate physical activity guidelines after SCAD?
What are the risks of exogenous hormone therapy and pregnancy after SCAD?
FMD indicates fibromuscular dysplasia; and SCAD, spontaneous coronary artery dissection.

Author Manuscript
Author Manuscript
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